18FDG PET/CT in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type

Area of Science:

• Oncology
• Nuclear Medicine
• Dermatology

Background:

• Primary cutaneous diffuse large B-cell lymphoma (PC-DLBCL) leg type is a rare and aggressive non-Hodgkin lymphoma.
• Accurate staging and treatment response assessment are critical for managing PC-DLBCL leg type.

Observation:

• An 86-year-old female presented with multiple cutaneous and subcutaneous nodules on her right lower limb.
• Initial whole-body F-FDG PET/CT revealed intense hypermetabolic activity in these lesions.
• The patient received rituximab combined with polychemotherapy.

Findings:

• F-FDG PET/CT demonstrated complete metabolic response after 4 and 8 cycles of treatment.
• The imaging modality effectively tracked the reduction in disease activity.
• No residual hypermetabolic activity was detected post-treatment.

Implications:

• This case highlights the significant role of F-FDG PET/CT in the initial staging of PC-DLBCL leg type.
• F-FDG PET/CT is valuable for monitoring treatment response in this rare lymphoma subtype.
• While no specific guidelines exist, F-FDG PET/CT should be considered in clinical practice for PC-DLBCL leg type management.